DermTech, Inc. (NASDAQ:DMTK) has announced agreements with Highmark Inc. to enhance access to the DermTech Melanoma Test (DMT). The contracts are in addition to a favorable coverage policy. Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, West Virginia, Delaware and New York. The DMT test results provide clinicians with objective and actionable genomic data for a suspicious lesion, improve patient care and reduce healthcare costs.